Company / Operating Cash Flow
Aquestive Therapeutics, Inc. Operating Cash Flow History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow
-$52.4M
FY2025
5-year range
-$52.4M / -$6.4M
FY2021-FY2025
Trend
-46.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from -$6M to -$52M over the past 2 years.
Based on SEC 10-K filings.
-$52M in FY2025.
Declined from -$6M to -$52M over the past 2 years.
Operating Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, operating cash flow decreased 46.6% year-over-year.
- Peak operating cash flow was recorded in FY2018.
- Lowest operating cash flow in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$52.4M | -46.6% |
| FY2024 | -$35.8M | -460.5% |
| FY2023 | -$6.4M | +35.0% |
| FY2022 | -$9.8M | +78.4% |
| FY2021 | -$45.5M | +24.5% |
| FY2020 | -$60.2M | -363.5% |
| FY2019 | -$13.0M | -323.1% |
| FY2018 | $5.8M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026